Former President of the Global Business Unit at Schering AG, Dr. Joachim-Friedrich Kapp, MD, PhD, to Lead Aditx Therapeutics ...
August 14 2020 - 8:00AM
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Dr. Joachim-Friedrich Kapp, MD, PhD
as Vice President of Clinical Development, Autoimmunity, effective
immediately.
In his newly created role as Vice President of
Clinical Development, Autoimmunity, Dr. Kapp will be responsible
for all preparation, execution, regulatory and budgetary matters
relating to Aditxt’s planned 2021 Phase I/IIA clinical trials.
Co-Founder and Chief Executive Officer of
Aditxt, Amro Albanna, stated, “Aditxt’s therapeutics focus on
reprogramming the immune system is one of our two core
segments. We are very pleased to have Dr. Kapp lead our
autoimmunity clinical development starting with Psoriasis. Dr.
Kapp’s experience and leadership in executive and advisory roles is
a welcomed addition to the Aditxt team. Dr. Kapp understands and
has worked with the regulatory framework in both the US and in
Europe. We are excited that Dr. Kapp will lead Aditxt in this
critical role as we prepare for our upcoming Phase I/IIA
trials.”
Dr. Kapp brings over 3 decades of experience
working with global healthcare corporations and regulatory agencies
such as the FDA and EMA. Notably, he is the former President of the
Global Business Unit, (GBU) Specialized Therapeutics and member of
the Executive Committee at Schering AG. He is a member of the
Supervisory Board at Allistro Capital, a German based private
equity fund, where he serves as the fund’s chemical industry
expert. Dr. Kapp is also Vice Chairman of the Supervisory Board at
CellGenix, a leading global supplier of high quality raw and
ancillary materials for the expanding market of cell and gene
therapy. Dr. Kapp is Board Certified in Pharmacology, Toxicology,
and Clinical Pharmacology.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Forward looking statements include
statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product
development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated June 29, 2020, that was filed with the U.S.
Securities and Exchange Commission under File No. 333-235933, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the U.S.
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
PCG Advisory Jeff Ramson
Chief Executive Officer
IR@aditxt.com 646-762-4518
www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024